[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hematologic-neoplasms\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hematologic-neoplasms":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,24,0,[8,49,62,92,119,147,175,198,221,240,271,297,323,343,368,400,424,446,467,491,516,545,569,595],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":31,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100053437","phase-2-stem-cell-transplantation-for-participants-with-germline-runx1-associated-blood-cancers-100053437",false,"NCT07524530","Stem Cell Transplantation for Participants With Germline RUNX1 Associated Blood Cancers","Phase II Haploidentical Hematopoietic Stem Cell Transplantation for Participants With Germline RUNX1 Associated Hematologic Malignancies","* INCLUSION CRITERIA:\n* Affected participants (Recipients)\n\n  * History of deleterious or suspected deleterious (defined as P\u002FLP or VUS with RUNX1 phenotype) germline RUNX1 mutation as defined by ClinVar (nih.gov)\n  * Histological confirmation of a myeloid malignancy - acute or chronic leukemia (\\\u003C5% marrow blasts preferred) or myelodysplastic syndrome\u002Fmyeloproliferative neoplasms (MDS\u002FMPN) (\\\u003C10% marrow blasts preferred). Participants may be treated on this study to achieve preferred blast cutoffs. Participants with poorly responsive or relapsed disease remain eligible and may proceed as the graft-versus-leukemia (GVL) effect may produce cures.\n\nSubjects requiring standard therapies to prepare for HCT should ideally be referred to this study in remission, if possible. However, sometimes disease status changes during evaluation for HCT and it is necessary to establish disease control through the administration of standard therapies during evaluation for HCT. If ongoing therapy for the underlying disease outside of the NIH is not in the best interest of the subject according to the clinical judgment of the NIH PI, then the subject may receive standard treatment for his\u002Fher underlying hematologic malignancy as a bridge to HCT on this protocol, prior to starting the research phase of the study. If it becomes apparent that the subject will not be able to proceed to HCT, then he\u002Fshe must come off study. Subjects receiving standard therapy will be told about the therapy, associated risks, potential benefits, alternatives to the proposed therapy, and the availability of receiving the same treatment elsewhere, outside of a research protocol.\n\n* Availability of a haploidentical donor (HLA-match only).\n* Age \\>= 4 and \\\u003C= 70 years\n* Karnofsky (\\>=16 years) or Lansky (\\\u003C16 years) \\>=60%\n* For human immunodeficiency virus (HIV)-infected participants, participant must be on effective anti-retroviral therapy, without uncontrolled opportunistic infection and have approval via Transplant Infectious Disease consultation. Consider donor with CCR5(delta)32 homozygosity for these participants.\n* For individuals with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load (VL) must be undetectable on suppressive therapy, if indicated.\n* Participants with a history of hepatitis C virus (HCV) infection must have been treated and cured. Participants with active HCV infection who are currently on treatment must have an undetectable HCV VL.\n* Contraception as follows:\n\n  ---Women of child-bearing potential (WOCBP) must agree to use highly effective contraception (hormonal, intrauterine device \\[IUD\\], abstinence, surgical sterilization) at the study entry and up to and 12 months post conditioning and\u002For post-transplant.\n* Men that can father a child must agree to use an effective method of contraception (barrier, surgical sterilization, abstinence) at the study entry and up to 12 months posttransplant or 4 months after conditioning if transplant is not done. We also will recommend men that can father children with partners that can bear children ask their partners to be on highly effective birth control (hormonal, IUD, surgical sterilization). Men that can father children must not freeze or donate sperm within the same period.\n* Breastfeeding participants must be willing to discontinue breastfeeding during the study and for 12 months post-transplant or 1 week after conditioning if transplant is not done.\n* Willingness to remain in the NIH hospital or, if discharged, stay close to the NIH (30 minutes drive), for a minimum of 100 days after transplant or longer if there are complications. The participants must commit to having an adult caregiver with them during the first 100 days after the transplant\n* Participants or parent\u002Fguardian\u002Flegally authorized representative must be able to understand and willing to sign a written informed consent document.\n* Additional criteria for recipients suitable for MAC\n\n  * Age \\\u003C= 65 years\n  * HCT-CI \\\u003C4\n  * Pulmonary function tests (PFTs): Forced expiratory volume in the first second (FEV1) and adjusted diffusion capacity of carbon monoxide (DLCO) \\>=66%, without dyspnea at rest or oxygen requirement. If too young to cooperate with PFTs, must have \\>=92% oxygen saturation on room air and no dyspnea at rest.\n  * Left ventricular ejection fraction (LVEF) \\>=50% by echocardiogram (ECHO) or Multigated Acquisition (MUGA) scan (101)\n  * Recipients must have adequate organ function as defined below:\n\n    * Total bilirubin \\\u003C1.5 x institutional upper limit of normal (iULN) (unless Gilbert disease, hemolysis)\n    * Aspartate aminotransferase (AST) \u002F Alanine aminotransferase (ALT) \\\u003C=2.5 x iULN (unless therapy related and will improve in discussion with the National Institute of Diabetes and Digestive and Kidney Diseases \\[NIDDK\\])\n    * Creatinine within normal institutional limits or 24-hour urine or calculated creatinine clearance \\>=60 mL\u002Fmin\u002F1.73 m\\^2 for individuals with creatinine levels above institutional normal (calculated using the Chronic Kidney Disease Epidemiology Collaboration \\[CKD-EPI\\] equation)\n* Additional criteria for recipients suitable for RIC\n\n  * Age \\\u003C=70 years\n  * PFTs: FEV1 and DLCO \\>=50%, without dyspnea at rest or oxygen requirement. If too young to cooperate with PFTs, must have \\>=92% oxygen saturation on room air and no dyspnea at rest\n  * LVEF \\>=40% by ECHO or MUGA obtained within 2 months of HSCT (Children s Oncology Group \\[COG\\] criteria).\n  * Recipients must have adequate organ function as defined below:\n\n    * Total bilirubin \\\u003C2.5 x iULN (unless Gilbert disease, hemolysis)\n    * AST\u002FALT \\\u003C3.5 x iULN (unless therapy related and will improve in discussion with NIDDK)\n    * Creatinine within normal institutional limits or 24-hour urine or calculated creatinine clearance \\>=50 mL\u002Fmin\u002F1.73 m\\^2 for individuals with creatinine levels above institutional normal (calculated using the CKD-EPI equation)\n* Unaffected participants\n\n  * Haploidentical donors\n\n    ----Age \\>=4 years\n  * Participants or parent\u002Fguardian must be able to understand and willing to sign a written informed consent document.\n  * Unaffected family members\n\n    * Age \\>=18 years\n    * If the participant is a blood relative of the recipient, participant must be negative for RUNX1 mutations by molecular testing\n    * Participants must be able to understand and willing to sign a written informed consent document.\n\nEXCLUSION CRITERIA:\n\n-All participants\n\n* Recipients who are receiving any investigational agent except virus specific T cells (VST)\n* Active non-hematologic malignancies\n* History of allergic reactions attributed to compounds of similar chemical or biologic composition to the drugs used in study.\n* Participants with the following cardiac conditions: symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia (except atrial fibrillation if cleared by cardiology consultation)\n* Participants without access to medical care at home.\n* Positive serum or urine beta-human chorionic gonadotropin (beta-hCG) test at screening\n* Uncontrolled intercurrent illness evaluated by history, physical exam, and laboratory studies or situations that would limit compliance with study requirements, interpretation of results or that could increase risk to the participant","ALL","4 Years","70 Years",{"count":20,"type":21},98,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","Background:\n\nSome blood cancers can be caused by germline variants (changes) in a person s RUNX1 gene. Germline variants are genetic inherited changes a person is born with. Stem cell transplants are used to treat many diseases including blood cancers. Stem cell transplantation for patients with germline RUNX1 mutation driven blood cancers is standard of care and available in most major medical centers. The difference with this transplantation protocol is that it is prospective, only available to participants with germline RUNX1 variants and designed to determine the extent to which tailoring chemotherapy and supportive care medication doses for each individual patient may improve outcomes compared to data derived from retrospective transplantation protocols for patients with RUNX1 varinats which is less accurate.\n\nObjective:\n\nThe primary objective of this protocol is to determine how tailored doses of chemotherapy and supportive care medications may improve disease free survival as compared to historical\u002Fexpected disease free survival.\n\nEligibility:\n\nPeople aged 4 to 70 years with blood cancer caused by a RUNX1 gene mutation. Other participants are also needed: (1) stem cell donors; (2) relatives who do not have a mutation in the RUNX1 gene; and (3) healthy volunteers.\n\nDesign:\n\nParticipants with blood cancer will be screened during approximately 1-3 months before transplatation. They will have blood tests and tests of their heart and lung function. A sample of bone marrow may be taken.\n\nA flexible tube (central line) will be inserted into a vein in participants chest or lower neck. This line will remain in place during the hospitalization and be used to draw blood and administer drugs. These lines are almost always transitioned to a peripherally inserted central catheter (PICC) line at the time of hospital discharge.\n\nParticipants will be inpatient for 4 to 5 weeks. They will receive drugs to prepare their body for the stem cell transplant. Some may also receive radiation treatment. Other tests will include imaging scans. The stem cell transplant will be given through the central line.\n\nAfter discharge from the clinic, participants will have follow-up visits at least once per week for approximately 100 days. Then they will have follow-up clinic visits for 3 years.\n\nDonors, relatives, and healthy volunteers may provide samples of blood, stool, and saliva. Adults may also opt to provide samples of skin and bone marrow.",[27,28,29,30],"Core Binding Factor Alpha Subunits","Hematologic Neoplasms","Leukemia","Lymphoma",[32,33,34,35],"RUNX1","Haploidentical Hematopoietic Stem Cell Transplant","Germline RUNX1","germline RUNX1-aassociated myeloid malignancy","NOT_YET_RECRUITING","2026-07-10",{"date":39,"type":40},"2026-07-13","ACTUAL",{"date":42,"type":21},"2026-07-16",{"date":44,"type":21},"2036-06-01",{"name":46,"class":47},"National Cancer Institute (NCI)","NIH",1,{"id":50,"slug":4,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":51,"targetDuration":4,"studyType":22,"phases":52,"briefSummary":25,"conditions":53,"keywords":54,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":55,"lastUpdatePostDateStruct":56,"startDateStruct":58,"completionDateStruct":60,"leadSponsor":61,"locationsCount":48},"100633272",{"count":20,"type":21},[24],[27,28,29,30],[32,33,34,35],"2026-07-01",{"date":57,"type":40},"2026-07-02",{"date":59,"type":21},"2026-07-07",{"date":44,"type":21},{"name":46,"class":47},{"id":63,"slug":64,"hasResults":11,"nctId":65,"briefTitle":66,"officialTitle":67,"acronym":4,"eligibilityCriteria":68,"healthyVolunteers":11,"sex":16,"minAge":69,"maxAge":70,"enrollmentInfo":71,"targetDuration":4,"studyType":22,"phases":73,"briefSummary":75,"conditions":76,"keywords":78,"overallStatus":83,"whyStopped":4,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":48},"100605401","phase-1-phase-i-trial-integrating-hla-haploidentical-anti-cd19-car-t-cells-with-post-transplantation-cyclophosphamide-based-hla-haploidentical-hematopoietic-cell-transplantation-100605401","NCT07162038","Phase I Trial Integrating HLA-Haploidentical Anti-CD19 CAR-T Cells With Post-Transplantation Cyclophosphamide-Based HLA-Haploidentical Hematopoietic Cell Transplantation","Phase I Trial Integrating HLA-Haploidentical Anti-CD19 CAR T Cells With Post-Transplantation Cyclophosphamide-Based HLA-Haploidentical Hematopoietic Cell Transplantation","-INCLUSION CRITERIA - Recipient\n\n1. Participants with high or very high-risk hematologic malignancies, as defined by the revised Disease Risk Index (DRI), or malignancy that remains persistently MRD+ (by flow cytometry, cytogenetics, FISH, PCR, or NGS) on most recently assessed disease specimen (within 2 months of initiating conditioning).\n2. Hematologic malignancy must be CD19+ (uniform expression on immunohistochemistry or \\>= 80% on flow cytometry) as confirmed by CD19 IHC assay (BT51E) or flow cytometry (BD QuantiBRITE(TM) Beads PE Fluorescence Quantitation Kit). (Participants do not have to have refused or lack access to commercial anti-CD19 CAR-T-cell therapies since this study focuses on the integration of CAR-T cells and HCT and not specifically the CAR-T cells themselves; furthermore the construct used to manufacture this product is the same as used in a current commercial product, but developed from a new batch and with a similar but not identical manufacturing process.)\n3. Age 18-75\n4. Karnofsky \\>= 60%.\n5. Participants must have adequate organ and marrow function as defined below:\n\n   * Cardiac ejection fraction \\>= 45% by 2D echocardiography;\n   * Forced expiratory volume-1 (FEV-1) and diffusing capacity of the lung for carbon monoxide (DLCO) (corrected for hemoglobin) all of \\>= 50% predicted;\n   * Estimated serum creatinine clearance of \\>= 60 ml\u002Fminute\u002F1.73m\\^2 calculated using eGFR in the clinical lab (participants with estimated serum creatinine clearance less than 60 may have measured creatinine clearance performed and if \\>= 60 will be considered eligible);\n   * Total bilirubin \\\u003C= 2X the upper limit of normal (participants with documented or suspected Gilbert s are exempt from this requirement);\n   * Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) \\\u003C= 5X the upper limit of normal.\n6. At least one available HLA-haploidentical donor\n7. Women of child-bearing potential (WOCBP) must agree to use a highly effective method of contraception (hormonal, intrauterine device (IUD), surgical sterilization, abstinence) at the study entry and for 1 year after transplant (restriction period).\n\n   Men must agree to use an effective method of contraception (barrier, surgical sterilization, abstinence) at the study entry and for 1 year after transplant. We also will recommend men with female partners of childbearing potential to ask female partners to be on highly effective birth control (hormonal, intrauterine device (IUD), surgical sterilization). Men must not freeze or donate sperm within the same period.\n8. Breastfeeding participants must be willing to discontinue breastfeeding from study treatment initiation through 1 year after transplant.\n9. Participants seropositive for human immunodeficiency virus (HIV) not due to intravenous immunoglobulin, must have been on effective combination anti-retroviral therapy for 6 months and without detectable viral load prior to the beginning of conditioning.\n10. For participants seropositive for hepatitis B virus (HBV) core antibody not due to intravenous immunoglobulin, a HBV viral load should be undetectable.\n11. Participants seropositive for hepatitis C virus (HCV) not due to intravenous immunoglobulin must have been treated and cured. For participants with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load.\n12. Ability of participant to understand and the willingness to sign a written informed consent document.\n13. Ability and willingness of participant to co-enroll on 20-C-0051: Gene Therapy Follow Up Protocol for Subjects Previously Enrolled in NCI for Immuno-Oncology Studies\n\n14 Willingness to remain in the NIH hospital or, if discharged, stay close to the NIH (\\\u003C60 minutes drive), for a minimum of 100 days after transplant or longer if there are complications. Participants must commit to having an adult caregiver with them during the first 100 days after transplant in case of discharging from the hospital before 100 days.\n\nINCLUSION CRITERIA - Donor\n\n1\\. Related donor (age \\>=12) deemed suitable, eligible, and willing to donate, per clinical evaluations, who are additionally willing to donate blood, bone marrow, and stool for research. Related donors will be evaluated in accordance with existing Standard Policies and Procedures for determination of eligibility and suitability for clinical donation.\n\nEXCLUSION CRITERIA - Recipient\n\n1. Participants who are receiving any other investigational agents within 3 weeks prior to the beginning of conditioning.\n2. Active CNS involvement of primary hematologic malignancy\n3. Active malignancy of non-hematopoietic type (excluding non-melanoma skin cancers) which is metastatic, relapsed\u002Frefractory to treatment, or locally advanced and not amenable to intended curative treatment per standard of care.\n4. Prior checkpoint inhibitor therapy within 6 weeks prior to the beginning of conditioning.\n5. Prior history of seizure.\n6. Uncontrolled infection.\n7. History of allergic reactions attributed to compounds of similar chemical or biologic composition to study agents used in study.\n8. Positive beta-HCG serum or urine pregnancy test performed in females of childbearing potential at screening. (A low positive test in a post-menopausal woman may not be exclusionary if deemed not indicative of pregnancy per gynecology.)\n9. Uncontrolled intercurrent illness evaluated by medical history, physical exam, EKG, and laboratory testing (e.g., severe endocrinopathy, disseminated intravascular coagulation, profound electrolyte disturbance) that would make it unsafe to proceed with transplantation.\n\nEXCLUSION CRITERIA - donor\n\n1\\. Pregnancy","18 Years","75 Years",{"count":72,"type":21},155,[74],"PHASE1","Background:\n\nHigh-risk blood cancers (leukemias and lymphomas) often come back after treatment, and many cannot be cured with chemotherapy alone. These cancers may be treated and potentially cured in 2 ways: (1) Bone marrow transplant (allogeneic hematopoietic cell transplantation, or alloHCT) gives immune and blood stem cells from a donor. These new cells can attack the cancer and also grow into healthy blood. (2) Chimeric antigen receptor (CAR) T-cell therapy takes immune cells and changes them in a lab to better recognize and target certain cancers. But these 2 treatments are not usually given at the same time.\n\nObjective:\n\nTo test alloHCT and CAR-T cell therapy, used together, in people with high-risk blood cancers.\n\nEligibility:\n\nPeople aged 18 to 75 years with an aggressive blood cancer that has a protein on the surface called CD19. A healthy related donor aged 12 years or older is also needed; this donor may be a parent or child or may be some siblings or even extended family members, but has to be half-matched at something called the HLA (human leukocyte antigen).\n\nDesign:\n\nParticipants will be screened. They will have imaging scans, blood tests, and tests of their heart and lung function. They will have eye and dental exams. They may have fluid drawn from around their spinal cord (spinal tap) and tissue taken from inside a bone (bone marrow biopsy).\n\nHealthy donors will provide bone marrow, immune cells, and about 9 tablespoons of blood for both the recipient s treatment and for research. They will also provide stool, saliva, and oral swabs just for research.\n\nRecipient participants will stay in the hospital for 4 to 6 weeks. They will be given drugs over 6 days to prepare for the cell therapies. Both the donor bone marrow cells and CAR-T-cells will be given through a tube inserted into a vein. They will receive drugs to reduce complications after the treatments.\n\nParticipants will remain within a 1-hour drive of the hospital for 2 to 3 months after they leave the hospital. They will have frequent visits during that time. They will continue to have periodic follow-up visits for 5 years.\n\n...",[77,28],"Hematologic Malignancies",[79,80,81,82],"Chimeric-Antigen-Receptor T-cell Therapy","High Risk Hematologic Malignancy","CD19","Hematopoietic Cell Transplant","RECRUITING","2026-06-26",{"date":86,"type":40},"2026-06-29",{"date":88,"type":40},"2025-11-14",{"date":90,"type":21},"2034-10-01",{"name":46,"class":47},{"id":93,"slug":94,"hasResults":11,"nctId":95,"briefTitle":96,"officialTitle":97,"acronym":98,"eligibilityCriteria":99,"healthyVolunteers":11,"sex":16,"minAge":69,"maxAge":4,"enrollmentInfo":100,"targetDuration":4,"studyType":22,"phases":102,"briefSummary":104,"conditions":105,"keywords":106,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":111,"startDateStruct":112,"completionDateStruct":114,"leadSponsor":116,"locationsCount":4},"100644653","take5care-a-self-management-educational-intervention-100644653","NCT07674212","Take5Care+: A Self-management Educational Intervention","Take5Care+: A Self-management Educational Intervention to Support the Haematology Patients' Journey Following a Neoplastic Diagnosis.","Take5Care+","Inclusion Criteria:\n\n* 18 years or older.\n* Have been diagnosed within the last 3 months with one of the eligible conditions listed in Table 1.\n* Be managed with either:\n\n  * Active monitoring, or\n  * Non-intensive oral therapy, defined as outpatient oral regimens that do not require inpatient initiation and have lower expected toxicity (e.g., BTK inhibitors, TKIs, interferon, lenalidomide, hydroxycarbamide, low-dose alkylators).\n* Have ECOG Performance Status 0-2.\n* Be able to give informed consent.\n* Be judged suitable for participation by the treating clinician.\n\nExclusion Criteria:\n\n* Receiving intensive chemotherapy, immunotherapy, IV combination regimens, cellular therapy, radiotherapy or treatments requiring inpatient initiation.\n* Received or expected to require regular blood product transfusions\n* Life expectancy \\\u003C12 months.\n* Acutely terminal illness.\n* ECOG ≥3.\n* Cognitive impairment that would prevent the patient from giving informed consent, or reliably completing the daily action and follow-up assessments\n* Pregnant or lactating.\n* Currently participating in a CTIMP or other behavioural research intervention.\n* Age \\\u003C18.\n* Unstable, uncontrolled, or severe comorbidities:\n\n  * Uncontrolled heart failure, unstable angina, or MI \\\u003C3 months.\n  * Stroke\u002FTIA \\\u003C3 months.\n  * Severe\u002Funstable COPD or asthma with recent exacerbations.\n  * Poorly controlled diabetes\n  * Severe psychiatric illness interfering with participation.\n* Concurrent active malignancy requiring systemic therapy.\n* Any other condition that, in the investigator's judgement, would compromise safe participation.",{"count":101,"type":21},20,[103],"NA","Patients who are diagnosed with haematological malignancies may feel that they have little or no control over their health which can be distressing. However, a diagnosis can also be the opportunity for a \"teachable moment\" during which patients are more likely to open to behaviour change, which can positively impact on their health and wellbeing. Take Five to Age Well (Take Five) was designed to empower people to achieve effective, long-term self-management of health by introducing healthy habits in 30 days.\n\nIn collaboration with Northampton General Hospital (NGH) the current study will recruit newly diagnosed haematology patients who are either being actively monitored or only on non-intensive treatment to take part in a self-managed behaviour change intervention. This is primarily a feasibility study to inform main trials in the future.\n\nThe main aim of the research is:\n\n1. To assess the feasibility of using Take5Care+ with patients newly diagnosed with indolent or chronic haematological malignancies, recruited via hospital departments\n\n   There are also secondary aims, including:\n2. To assess the impact of participating in Take5Care+ on patients' self-reported health and well-being, healthy behaviours and sense of control, knowledge and management of health\n3. To explore the perceptions of patients and clinicians about their participation in the Take5Care+ Patients who wish to take part will be asked to fill out a survey at baseline, complete a \"challenge\" where they commit to a healthy action for 30 days, fill out a second survey immediately after and a third survey three months later. Patients may also consent to participating in an interview post-challenge. Giving consent and completing the baseline survey will take place in NGH but the challenge is self-managed at home and remotely supported. Survey 2, Survey 3 and the optional interviews are also carried out online or over the phone.",[28],[107,108,109],"hematologic neoplasms","pilot intervention","feasibility study","2026-06-23",{"date":86,"type":40},{"date":113,"type":21},"2026-07",{"date":115,"type":21},"2027-10",{"name":117,"class":118},"Jitka Vseteckova","OTHER",{"id":120,"slug":121,"hasResults":11,"nctId":122,"briefTitle":123,"officialTitle":124,"acronym":4,"eligibilityCriteria":125,"healthyVolunteers":126,"sex":16,"minAge":127,"maxAge":128,"enrollmentInfo":129,"targetDuration":4,"studyType":131,"phases":4,"briefSummary":132,"conditions":133,"keywords":136,"overallStatus":83,"whyStopped":4,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":141,"startDateStruct":143,"completionDateStruct":4,"leadSponsor":145,"locationsCount":48},"100063184","collection-of-tissue-specimens-from-patients-with-solid-tumors-or-blood-disorders-and-their-hla-compatible-family-members-100063184","NCT00071045","Collection of Tissue Specimens From Patients With Solid Tumors or Blood Disorders and Their HLA-Compatible Family Members","Collection of Blood, Bone Marrow, Urine, and\u002For Tissue Samples From Patients With Solid Tumors, Hematological Malignancies or Non-Malignant Hematologic Disorders or HLA Compatible Family Members","* INCLUSION CRITERIA:\n\nThe subject carries the diagnosis of malignant solid tumor or a malignant or non-malignant hematologic disorder, and is being screened at the NIH for eligibility for an NIH protocol.\n\nOR\n\nThe subject carries the diagnosis of malignant solid tumor or a malignant or non-malignant hematologic disorder, and is already enrolled on a protocol at the NIH Clinical Center.\n\nOR\n\nThe subject is a related HLA-compatible family member of a patient (bearing a diagnosis of malignant solid tumor or a malignant or non-malignant hematologic) being evaluated for or already enrolled on a protocol at the NIH Clinical Center and is identified as a potentially suitable donor of allogeneic hematopoietic stem cells for transplantation.\n\nOR\n\nThe subject carries the diagnosis of malignant solid tumor or a malignant or non malignant hematologic disorder or a bone marrow failure condition and is not available to participate in an NIH Clinical Center treatment protocol, or travel to the NIH clinical center, but is referred for participation through their home health care provider.\n\nThe subject or the subject's Legally Authorized Representative (LAR) is able to understand the investigational nature of the study and provide informed consent after initial counseling by an AI. Separate consent forms for interventional or surgical procedures will be obtained after explanation of the specific procedure.\n\nAge 2 years and older (no upper limit)\n\nEXCLUSION CRITERIA:\n\nSubjects or LAR unable to comprehend the investigational nature of the protocol.\n\nAge less than 2 years",true,"2 Years","100 Years",{"count":130,"type":21},6000,"OBSERVATIONAL","This study will collect biological samples for use in research experiments aimed at better understanding the clinical features of certain diseases. The specimens may be used to evaluate the effectiveness of known therapies, refine treatment approaches, identify potential new therapies, and explore opportunities for disease prevention.\n\nThe following individuals 2 years of age or older may be eligible for this study:\n\n* Patients with a cancerous solid tumor or a cancerous or non-cancerous blood disorder who are being screened for or who are enrolled in a treatment study at the NIH Clinical Center\n* HLA-compatible donor family members (18 years of age or older) of the above patients who are being evaluated for or are enrolled in an NIH study as a stem cell transplant donor\n* Patients with a cancerous solid tumor or a cancerous or non-cancerous blood disorder or a bone marrow failure condition who cannot participate in an NIH treatment protocol or travel to the NIH Clinical Center and who are referred for participation through their home health care provider.\n\nResearch samples will be collected from participants when blood is drawn or bone marrow, urine, or stool is collected, or tumor or other tissue is biopsied as part of their general medical care. Investigators may periodically request an additional sample of blood, stool, or urine. Participants who are 18 years of age or older may donate a large number of white blood cells through a procedure called leukapheresis. This procedure is not part of general medical care and would be done for research purposes only. For apheresis, a catheter (plastic tube) is placed in a vein in the subject's arm. Blood flows from the vein into a cell separator machine, where the white cells are separated from the red cells, platelets, and plasma by a spinning process. The white cells are removed and collected, and the rest of the blood is returned to the subject through a second tube placed in the other arm.\n\n...",[134,28,135],"Neoplasms","Healthy Volunteers",[137,138,139,140],"Tissue Procurement","Sample Collection","Laboratory Research Specimens","Natural History",{"date":142,"type":40},"2026-06-24",{"date":144,"type":40},"2003-10-08",{"name":146,"class":47},"National Heart, Lung, and Blood Institute (NHLBI)",{"id":148,"slug":149,"hasResults":11,"nctId":150,"briefTitle":151,"officialTitle":151,"acronym":4,"eligibilityCriteria":152,"healthyVolunteers":126,"sex":16,"minAge":153,"maxAge":154,"enrollmentInfo":155,"targetDuration":4,"studyType":22,"phases":157,"briefSummary":158,"conditions":159,"keywords":160,"overallStatus":83,"whyStopped":4,"lastUpdateSubmitDate":166,"lastUpdatePostDateStruct":167,"startDateStruct":169,"completionDateStruct":171,"leadSponsor":173,"locationsCount":174},"100436126","phase-1-phase-iii-study-to-reduce-post-transplantation-cyclophosphamide-dosing-for-older-or-unfit-patients-undergoing-bone-marrow-transplantation-for-hematologic-malignancies-100436126","NCT04959175","Phase I\u002FII Study to Reduce Post-transplantation Cyclophosphamide Dosing for Older or Unfit Patients Undergoing Bone Marrow Transplantation for Hematologic Malignancies","-INCLUSION CRITERIA - Recipient\n\n1. Subjects must have a histologically or cytologically confirmed hematologic malignancy with standard indication for allogeneic hematopoietic cell transplantation including, but not limited to, one of the following:\n\n   * Acute myeloid leukemia in morphologic complete remission (\\\u003C5% blasts in the bone marrow, no detectable abnormal peripheral blasts, and no extramedullary disease)\n   * B-cell acute lymphoblastic leukemia in first or subsequent complete remission\n   * T-cell acute lymphoblastic leukemia in first or subsequent complete remission\n   * Myelodysplastic syndrome of intermediate or higher score by the Revised International Prognostic Scoring System (IPSS-R)\n   * Primary myelofibrosis of intermediate-2 or higher risk by the DIPSS\n   * Chronic myelomonocytic leukemia\n   * Chronic myelogenous leukemia resistant to or intolerant of \\>=3 tyrosine kinase inhibitors or with history of accelerated phase or blast crisis\n   * B-cell lymphoma including Hodgkin lymphoma that has relapsed within 1 year of completion of primary treatment, after autologous transplantation or has progressed through at least 2 lines of therapy\n   * Chronic lymphocytic leukemia with 17p deletion and\u002For unmutated IgHV or refractory or intolerant of both BTK and PI3K inhibitors\n   * Mature T or NK neoplasms as defined in the WHO guidelines of sufficient type and severity for allogeneic HCT based on the Prognostic Index for T-cell lymphoma (PIT) score of low-intermediate risk or higher60 or on recently published clinical practice guidelines\n   * Hematologic malignancy of dendritic cell or histiocytic cell type\n   * Multiple myeloma, stage III, relapsing after therapy with both a proteasome inhibitor and an immunomodulatory drug (IMiD)\n2. Age 60-85 years, or age 18-60 years and unfit for myeloablative conditioning. Reasons for unfitness for myeloablative conditioning include:\n\n   * Prior myeloablative HCT\n   * Prior exposure to inotuzumab, gemtuzumab, or other agent that increases the risk for sinusoidal obstruction syndrome.\n   * Significant organ dysfunction (e.g., creatinine or liver enzymes above the upper limit of normal or EGFR \\\u003C=70 ml\u002Fmin\u002F1.73sq.m; prior sinusoidal obstruction syndrome, hepatic fibrosis, hepatic steatosis, or nodular regenerative hyperplasia; reduced ejection fraction \\\u003C55% or focal hypokinesis, FEV1 or adjusted DLCO \\\u003C75% of predicted)\n   * Hematopoietic Cell Transplantation- Comorbidity Index (HCT-CI) \\>= 3\n   * Subject refusal of MAC (including subjects insistent on trying to maintain fertility)\n   * Pre-frail or frail by Fried s frailty phenotype\n   * Karnofsky performance score \\\u003C80\n   * Significant life-threatening toxicities associated with prior chemotherapy\n   * Co-morbidity considered by the treating physician to be exclusionary of MAC\n3. At least one potentially suitable HLA-matched related, HLA-haploidentical first degree or collateral related, HLA-matched unrelated, or \\>=5\u002F10 HLA-mismatched unrelated donor.\n4. Karnofsky performance score \\>=60\n5. Ability of subject to understand and the willingness to sign a written informed consent document.\n6. Adequate organ function defined as possessing all of the following:\n\n   * Cardiac ejection fraction \\>=35%;\n   * Forced expiratory volume-1, forced vital capacity, and diffusing capacity of the lung for carbon monoxide (corrected for hemoglobin) all of \\>=40% predicted;\n   * Serum creatinine clearance of \\>=45 ml\u002Fminute calculated using the Cockcroft-Gault equation;\n   * Total bilirubin \\\u003C=2X the upper limit of normal;\n   * Alanine aminotransferase and aspartate aminotransferase \\\u003C=5X the upper limit of normal.\n7. Nonmyeloablative conditioning is toxic to the developing human fetus and is teratogenic. For this reason, the following measures apply:\n\n   * Women of child-bearing potential (WOCBP) and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for at least one year post-transplant.\n   * Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately.\n   * WOCBP must have a negative serum or urine pregnancy test within 7 days prior to enrollment.\n8. For NIH treated subjects only: subjects requiring standard therapies to prepare for HCT should be referred in remission, if possible. However, these diseases are often aggressive and require swift evaluation for HCT while concurrently attempting to establish disease control through the administration of standard therapies. If ongoing therapy for the underlying disease outside of the NIH is not in the best interest of the subject according to the clinical judgment of the NIH PI, then the subject may receive standard treatment for his\u002Fher underlying hematologic malignancy as a bridge to HCT on this protocol, prior to starting the research phase of the study. If it becomes apparent that the subject will not be able to proceed to HCT, then he\u002Fshe must come off study. Subjects receiving standard therapy will be told about the therapy, associated risks, potential benefits, alternatives to the proposed therapy, and the availability of receiving the same treatment elsewhere, outside of a research protocol.\n\nEXCLUSION CRITERIA - Recipient:\n\n1. Subjects who are receiving any other investigational agents. Prior experimental therapies must have been completed at least 2 weeks prior to the date of beginning conditioning.\n2. Poorly controlled malignant indication for transplantation such as:\n\n   * Leukemia not having achieved morphologic remission (i.e. bone marrow blasts \\>5% or active extramedullary disease)\n   * Lymphoma not having achieved at least a partial response to prior chemotherapy or radiation\n3. Uncontrolled intercurrent illness that in the opinion of the site PI would make it unsafe to proceed with transplantation.\n4. The potential for some of the study medications to be transmissible via breast milk of nursing mothers is unknown. Because there is unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother, breastfeeding must be discontinued.\n5. Active malignancy of non-hematopoietic type which is: metastatic, relapsed\u002Frefractory to treatment, or locally advanced and not amenable to curative treatment, or limited disease treated with curative intent treatment within the last 2 years. This excludes nonmelanoma skin cancers.\n\nINCLUSION CRITERIA - Donor:\n\nRelated (age \\>=12) and unrelated (age \\>=18) donors deemed eligible (i.e., evaluated at NIH in accordance with existing institutional Standard Policies and Procedures or evaluated per the standards required by the IRB of the National Marrow Donor Program or applicable registry), and willing to donate research samples will be included.\n\nEXCLUSION CRITERIA - Donor:\n\nNone","12 Years","85 Years",{"count":156,"type":21},320,[74,24],"Background:\n\nCertain blood cancers can be treated with blood or bone marrow transplants. Sometimes the donor cells attack the recipient's body, called graft-versus-host disease (GVHD). The chemotherapy drug cyclophosphamide helps reduce the risk and severity of GVHD. Researchers want to learn if using a lower dose of cyclophosphamide may reduce the drug's side effects while maintaining its effectiveness. Such an approach is being used in an ongoing clinical study at the NIH with promising results, but this approach has not been tested for transplants using lower doses of chemotherapy\u002Fradiation prior to the transplant.\n\nObjective:\n\nTo learn if using a lower dose of cyclophosphamide will help people have a successful transplant and have fewer problems and side effects.\n\nEligibility:\n\nAdults ages 18-85 who have a blood cancer that did not respond well to standard treatments or is at high risk for relapse without transplant, and their donors.\n\nDesign:\n\nParticipants may be screened with the following:\n\nMedical history\n\nPhysical exam\n\nBlood and urine tests\n\nHeart and lung tests\n\nBody imaging scans (they may get a contrast agent)\n\nSpinal tap\n\nBone marrow biopsy\n\nParticipants will be hospitalized for 4-6 weeks. They will have a central venous catheter placed in a chest or neck vein. It will be used to give medicines, transfusions, and the donor cells, and to take blood. In the week before transplant, they will get 2 chemotherapy drugs and radiation. After the transplant, they will get the study drug for 2 days. They will take other drugs for up to 2 months.\n\nParticipants must stay near NIH for 3 months after discharge for weekly study visits. Then they will have visits every 3-12 months until 5 years after transplant.\n\nParticipants and donors will give blood, bone marrow, saliva, cheek swab, urine, and stool samples for research.",[28],[161,162,163,164,165],"myeloablative conditioning","Chronic Graft-Versus-Host Disease","hematopoietic cell transplantation","Fludarabine","TOTAL BODY IRRADIATION","2026-06-10",{"date":168,"type":40},"2026-06-11",{"date":170,"type":40},"2021-09-23",{"date":172,"type":21},"2027-04-30",{"name":46,"class":47},2,{"id":176,"slug":177,"hasResults":11,"nctId":178,"briefTitle":179,"officialTitle":180,"acronym":4,"eligibilityCriteria":181,"healthyVolunteers":11,"sex":16,"minAge":69,"maxAge":4,"enrollmentInfo":182,"targetDuration":4,"studyType":22,"phases":184,"briefSummary":185,"conditions":186,"keywords":4,"overallStatus":83,"whyStopped":4,"lastUpdateSubmitDate":187,"lastUpdatePostDateStruct":188,"startDateStruct":190,"completionDateStruct":192,"leadSponsor":194,"locationsCount":197},"100636924","phase-1-a-study-of-jnj-95804306-for-relapsed-or-refractory-hematological-malignancies-100636924","NCT07572006","A Study of JNJ-95804306 for Relapsed or Refractory Hematological Malignancies","A Phase 1, First-in-human, Dose Escalation Study of JNJ-95804306 for Relapsed or Refractory Hematological Malignancies","Inclusion criteria:\n\nFor Arm A:\n\n* Have a diagnosis of: Acute myeloid leukemia (AML) per International Consensus Classification (ICC) 2022 or myelodysplastic syndromes (MDS) per world health organization (WHO) 2022 classified as moderate high, high, or very high-risk per the molecular international prognostic scoring system (IPSSM). All participants must have relapsed or refractory disease and have exhausted or are ineligible for standard therapeutic options\n* Body weight greater than or equal to (\\>=) 40 kilograms (kg)\n* Eastern cooperative oncology group (ECOG) performance status of 0 to 2\n\nFor Arm B:\n\n* Have a diagnosis of chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL\u002FSLL) that meets International workshop on chronic lymphocytic leukemia (iwCLL), National cancer institute (NCI) Working Group Guidelines which is relapsed or refractory and requires treatment with no other approved therapies available that would be more appropriate in the investigator's judgment. a. Participants must have received at least 2 prior lines of therapy; b. Participants who have received at least one prior line of therapy but are not eligible or do not have access to standard second line therapies, will be allowed to enroll\n* Body weight \\>= 40 kg\n* ECOG performance status of 0 to 2\n* Have clinically measurable disease\n* For US sites: Have a diagnosis of CLL\u002FSLL that meets iwCLL, NCI Working Group Guidelines which is relapsed or refractory and requires treatment with no other approved therapies available that would be more appropriate in the investigator's judgment. a. Participants must have received at least 2 prior lines of therapy\n\nExclusion criteria:\n\nFor Arm A:\n\n* Has acute promyelocytic leukemia according to world health organization (WHO) 2016 criteria or known active central nervous system (CNS) involvement of AML\u002FMDS, unless in specific cohort (s) per study evaluation team (SET) decision\n* Need for supplemental oxygen use to maintain adequate oxygenation\n* Have evidence of uncontrolled systemic viral, bacterial, or fungal infection. Antimicrobial prophylaxis is permitted\n* For US sites: Has acute promyelocytic leukemia according to WHO 2016 criteria or known active CNS involvement of AML\u002FMDS\n\nFor Arm B:\n\n* Need for supplemental oxygen use to maintain adequate oxygenation\n* Have evidence of uncontrolled systemic viral, bacterial, or fungal infection requiring initiation of parenteral treatment as medical intervention\n* Developed Richter's transformation or prolymphocytic leukemia\n* Known active CNS or leptomeningeal involvement of CLL\u002FSLL",{"count":183,"type":21},280,[74],"The purpose of Part 1 (Dose Escalation) of the study is to assess how safe and tolerable JNJ-95804306 is and to find out the most suitable dose (recommended phase 2 dose \\[RP2D\\]) of JNJ-95804306. The purpose of Part 2 (Dose Expansion) is to further assess the safety of JNJ-95804306 and determine the anti-tumor activity alone and\u002For when administered in addition to standard of care (SoC) therapy at the putative RP2D(s) regimens in participants with hematological malignancies (cancer that begins in blood-forming tissue, such as the bone marrow, or in the cells of the immune system). For US sites: The purpose of Part 1 (Dose Escalation) of the study is to assess how safe and tolerable JNJ-95804306 is and to find out the most suitable dose (recommended phase 2 dose \\[RP2D\\]) of JNJ-95804306. The purpose of Part 2 (Dose Expansion) is to further assess the safety of JNJ-95804306 and determine the anti-tumor activity alone at the putative RP2D(s) regimens in participants with hematological malignancies (cancer that begins in blood-forming tissue, such as the bone marrow, or in the cells of the immune system).",[28],"2026-06-04",{"date":189,"type":40},"2026-06-05",{"date":191,"type":40},"2026-05-13",{"date":193,"type":21},"2032-09-24",{"name":195,"class":196},"Janssen Research & Development, LLC","INDUSTRY",3,{"id":199,"slug":200,"hasResults":11,"nctId":201,"briefTitle":202,"officialTitle":203,"acronym":4,"eligibilityCriteria":204,"healthyVolunteers":126,"sex":16,"minAge":153,"maxAge":205,"enrollmentInfo":206,"targetDuration":4,"studyType":22,"phases":208,"briefSummary":209,"conditions":210,"keywords":211,"overallStatus":83,"whyStopped":4,"lastUpdateSubmitDate":187,"lastUpdatePostDateStruct":215,"startDateStruct":216,"completionDateStruct":218,"leadSponsor":220,"locationsCount":48},"100464386","phase-1-donor-lymphocyte-infusion-after-allogeneic-hematopoietic-cell-transplantation-for-high-risk-hematologic-malignancies-100464386","NCT05327023","Donor Lymphocyte Infusion After Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic Malignancies","Phase I\u002FII Study Using Prophylactic Donor Lymphocyte Infusion Early Post-Transplant After Allogeneic Hematopoietic Cell Transplantation Using Post-Transplantation Cyclophosphamide for High-Risk Hematologic Malignancies","* INCLUSION CRITERIA:\n\nInclusion Criteria - Recipient\n\n* Histologically or cytologically confirmed hematologic malignancy classified as high or very high disease risk by the Refined Disease Risk Index for HCT including one of the following:\n* Acute myeloid leukemia (AML) with favorable cytogenetics (t(8;21), inv(16), t(15,17)) with induction failure (persistent disease without first achieving remission of any type) or active relapse\n* AML with intermediate cytogenetics (not classified as favorable or adverse) with induction failure or active relapse (AML with intermediate cytogenetics in morphologic complete remission \\[CR\\] with minimal residual disease detectable by any modality also will be eligible)\n* AML with adverse cytogenetics (complex karyotype with \\>= 4 abnormalities) regardless of remission status\n* Low risk myelodysplastic syndrome (MDS) (\\\u003C= 5% blasts, including chronic myelomonocytic leukemia) with adverse cytogenetics (abnormal chromosome 7 or \\>= 4 abnormalities) with induction failure or active relapse\n* High risk MDS (RAEB-1 or RAEB-2) with intermediate-risk cytogenetics (no abnormal chromosome 7 or \\\u003C 4 abnormalities) with induction failure or active relapse\n* High risk MDS (RAEB-1 or RAEB-2) with adverse cytogenetics (abnormal chromosome 7 or \\>= 4 abnormalities) regardless of remission status\n* Acute lymphoblastic leukemia (ALL) in CR \\>= 2 or with induction failure or active relapse (ALL in CR1 with minimal residual disease detected also will be eligible)\n* Chronic myelocytic leukemia (CML) in blast crisis phase\n* Hodgkin lymphoma with stable or progressive disease\n* Mantle cell lymphoma with stable or progressive disease\n* Relapsed Burkitt lymphoma in CR or partial remission (PR)\n* Aggressive B-cell Non-Hodgkin Lymphoma (NHL) (e.g., diffuse large B-cell lymphoma, transformed indolent B-cell lymphoma) with stable or progressive disease\n* T-cell NHL with stable or progressive disease\n* Multiple myeloma (MM) with induction failure as defined by failure to achieve minimal response (CR, Very Good Partial Response \\[VGPR\\], or PR) or the development of progressive disease on primary therapy, or MM with active relapse as defined by previously treated myeloma that achieved a molecular response or better that then progressed\n* Age 18-65 years.\n* At least one potentially suitable HLA-haploidentical or HLA-matched donor\n* Karnofsky performance score \\>=60%\n* Recipient participants must have adequate organ function as defined below:\n* Cardiac ejection fraction \\>=45% by 2D ECHO;\n* Forced expiratory volume-1 (FEV-1), forced vital capacity (FVC), and diffusing capacity of the lung for carbon monoxide (DLCO) (corrected for hemoglobin) all of \\>=50% predicted;\n* Estimated serum creatinine clearance of \\>=60 ml\u002Fminute\u002F1.73m2 calculated using eGFR in the clinical lab;\n* Total bilirubin \\\u003C=2X the upper limit of normal;\n* Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) \\\u003C=3X the upper limit of normal.\n* Myeloablative conditioning is toxic to the developing human fetus and is teratogenic. For this reason, the following measures apply:\n* Women of child-bearing potential (WOCBP) and men must agree to use highly effective contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for at least one-year post-transplant.\n* WOCBP must have a negative serum or urine pregnancy test within 7 days prior to enrollment.\n\nInclusion Criteria - Donor\n\n-Related donor (age \\>=12) deemed suitable, eligible, and willing to donate, per clinical evaluations, who are additionally willing to donate blood, bone marrow, and stool for research. Related donors will be evaluated in accordance with existing Standard Policies and Procedures for determination of eligibility and suitability for clinical donation.\n\nEXCLUSION CRITERIA:\n\nExclusion Criteria - Recipient\n\n* Subjects who are receiving any other investigational agents. Prior experimental therapies must have been completed at least 3 weeks prior to the date of beginning conditioning.\n* Prior myeloablative conditioning for autologous or allogeneic HCT.\n* Active breastfeeding.\n* Active malignancy of non-hematopoietic type (excluding non-melanoma skin cancers) which is metastatic, relapsed\u002Frefractory to treatment, or locally advanced and not amenable to curative treatment. This excludes non-melanoma skin cancers.\n* Uncontrolled intercurrent illness (e.g. severe endocrinopathy, disseminated intravascular coagulation, profound electrolyte disturbance, active hepatitis, uncontrolled dental infection) that in the opinion of the PI would make it unsafe to proceed with transplantation.\n\nExclusion Criteria - Donor\n\nNone.","120 Years",{"count":207,"type":21},430,[74,24],"Background:\n\nPeople with blood cancers often receive blood or bone marrow transplants. But even with these treatments, the risk of relapse is high. Researchers want to see if giving the transplant recipient an infusion of lymphocytes (a type of white blood cell) from their transplant donor early after the transplant can reduce that risk.\n\nObjective:\n\nTo learn if giving donor lymphocytes early after a transplant will help reduce the risk of relapse for people with certain blood cancers.\n\nEligibility:\n\nAdults aged 18-65 with high-risk leukemia, lymphoma, myelodysplastic syndrome, or multiple myeloma that does not respond well to standard treatments and\u002For has a high risk of relapse. Healthy potential bone marrow and lymphocyte donor relatives aged 12 and older are also needed.\n\nDesign:\n\nParticipants will be screened with:\n\nPhysical exam\n\nBlood and urine tests\n\nSpinal tap\n\nEye exam\n\nDental exam\n\nHeart and lung tests\n\nImaging scans. A radioactive substance may be injected in their arm if a PET scan is needed.\n\nBone marrow aspiration and biopsy\n\nSome screening tests will be repeated during the study.\n\nParticipants will stay at the NIH hospital for about 4 weeks. They will receive a central venous catheter. They will get chemotherapy and other drugs starting 6 days before transplant. Then they will have their transplant. They will receive donor white blood cells 7 days later. They will give blood, bone marrow, urine, and stool samples for research. They must stay near NIH for at least 100 days after transplant.\n\nParticipants will have periodic follow-up visits for 5 years.\n\nHealthy donors will have 2-3 visits. They will give blood, bone marrow, white blood cells, and stool samples for research.\n\nParticipation will last for 5 years....",[28],[212,162,213,161,214],"Prophylactic Donor Lymphocyte Infusions","Immunotherapeutic Strategies","Steroid-Refractory Grade",{"date":189,"type":40},{"date":217,"type":40},"2022-05-23",{"date":219,"type":21},"2029-07-02",{"name":46,"class":47},{"id":222,"slug":223,"hasResults":11,"nctId":224,"briefTitle":225,"officialTitle":226,"acronym":4,"eligibilityCriteria":227,"healthyVolunteers":11,"sex":16,"minAge":69,"maxAge":4,"enrollmentInfo":228,"targetDuration":4,"studyType":22,"phases":230,"briefSummary":231,"conditions":232,"keywords":4,"overallStatus":83,"whyStopped":4,"lastUpdateSubmitDate":233,"lastUpdatePostDateStruct":234,"startDateStruct":235,"completionDateStruct":237,"leadSponsor":238,"locationsCount":48},"100638130","phase-1-a-phase-12-study-of-kk2430-in-participants-with-hematologic-neoplasms-100638130","NCT07629726","A Phase 1\u002F2 Study of KK2430 in Participants With Hematologic Neoplasms","A Phase 1\u002F2, Multicenter, First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of KK2430 in Participants With Hematologic Neoplasms","Inclusion Criteria:\n\n* Participants must be at least 18 years of age at the time of signing the informed consent.\n* At least 1 measurable diseases based on CT scan or MRI\n* Renal function values\n* Participants who have an ECOG PS score of 0, 1 or 2.\n* Be willing to provide a fresh tissue taken at current relapse at screening period.\n* Meet laboratory values at Screening i.e., ANC, Platelets, Corrected serum calcium, AST and ALT, Total bilirubin etc\n* Contraceptive use by \\[men and women\\] should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.\n* Women of childbearing potential and fertile men must agree to use highly effective contraceptive methods • At least 1 measurable diseases based on CT scan or MRI\n* Capable of giving signed informed consent\n* Health Information Access: Capable of providing access to personal health information via HIPAA authorization (US only).\n* Legal Status: Not under any administrative or legal supervision or institutionalization due to regulatory or juridical order.\n\nExclusion Criteria:\n\n* Medical Conditions\n* History of prior allogenic transplant.\n* Presence of Grade 2 peripheral neuropathy with pain.\n* Impaired cardiac function or clinically significant cardiac disease at Screening\n* Known active CNS involvement or clinical signs of meningeal involvement.\n* Evidence of HIV infection.\n* Active chronic HBV\u002FHCV infection,\n* Participants with positive anti-HBc must have a negative HBV-DNA quantification test result to be enrolled.\n* Receipt of any anti-tumor therapy within three weeks or at least five half-lives prior to the Screening visit, whichever is shorter.\n* Toxicities from prior anticancer therapies that have not resolved to Grade 1 or less except for abnormal clinical values alopecia and peripheral neuropathy (participants with Grade 1 or 2 neuropathy without pain are eligible for enrollment).\n* Use of systemic corticosteroids exceeding 10 mg\u002Fday of prednisone or equivalent within 14 days prior to the first dose",{"count":229,"type":21},72,[74,24],"KK2430 (\"Study Drug\") as a potential treatment for people with Hematologic Neoplasms. KK2430 is an experimental drug; it has not been approved for the treatment of any disease by health authorities such as United States Food and Drug Administration (FDA), and this is the first time it will be given to people. The purpose of this Study is to find out more information about KK2430, whether it is safe in humans, how the body processes it, and if it works for treating your condition.",[28],"2026-06-01",{"date":189,"type":40},{"date":236,"type":21},"2026-06",{"date":115,"type":21},{"name":239,"class":196},"Kyowa Kirin Co., Ltd.",{"id":241,"slug":242,"hasResults":11,"nctId":243,"briefTitle":244,"officialTitle":245,"acronym":246,"eligibilityCriteria":247,"healthyVolunteers":11,"sex":16,"minAge":248,"maxAge":4,"enrollmentInfo":249,"targetDuration":4,"studyType":22,"phases":251,"briefSummary":252,"conditions":253,"keywords":255,"overallStatus":83,"whyStopped":4,"lastUpdateSubmitDate":262,"lastUpdatePostDateStruct":263,"startDateStruct":265,"completionDateStruct":267,"leadSponsor":269,"locationsCount":48},"100292990","cognitive-training-intervention-and-attitudes-towards-genetics-100292990","NCT03094026","Cognitive Training Intervention and Attitudes Towards Genetics","Intervention Strategies to Improve Cognitive Functioning in Hematologic Cancer Survivors After Hematopoietic Cell Transplantation","cTAG","Inclusion Criteria:\n\n* ≥ 21 years old at time of allogeneic HCT performed at UAB\n* Outpatient and between 3 and 6 months post HCT\n* English speaking\n* Possess access to an internet-connected home computer\n\nExclusion criteria:\n\n* History of pre-existing neurological disorder or documented major psychiatric disorder; significant auditory, visual, or motor impairments\n* Participated in neuropsychological intervention within the past 6 months\n* History of color blindness","21 Years",{"count":250,"type":21},60,[103],"A pilot study to evaluate feasibility of enrollment of patients in an intervention to improve neurocognitive function in hematopoietic cell transplantation (HCT) survivors using the cognitive training Lumosity program. In addition, patients' interest in receiving information regarding genetic risk of cognitive impairment post-HCT will be measured.",[254,28,82],"Cognitive Impairment",[256,257,258,259,260,261],"Hematologic cancers","Hematopoietic cell transplantation","cognitive training","genetic knowledge","genetic attitude","adult cancer survivors","2026-04-16",{"date":264,"type":40},"2026-04-20",{"date":266,"type":40},"2017-08-21",{"date":268,"type":21},"2027-07",{"name":270,"class":118},"University of Alabama at Birmingham",{"id":272,"slug":273,"hasResults":11,"nctId":274,"briefTitle":275,"officialTitle":276,"acronym":277,"eligibilityCriteria":278,"healthyVolunteers":11,"sex":16,"minAge":69,"maxAge":4,"enrollmentInfo":279,"targetDuration":4,"studyType":22,"phases":281,"briefSummary":282,"conditions":283,"keywords":285,"overallStatus":83,"whyStopped":4,"lastUpdateSubmitDate":289,"lastUpdatePostDateStruct":290,"startDateStruct":291,"completionDateStruct":293,"leadSponsor":295,"locationsCount":48},"100632909","llm-generated-plain-language-patient-synopses-to-improve-comprehension-in-hematology-and-oncology-oncopal-100632909","NCT07519811","LLM-Generated Plain-Language Patient Synopses to Improve Comprehension in Hematology and Oncology (oncOPAL)","Prospective Randomized Controlled Trial to Evaluate Locally Implemented Large Language Models (LLMs) for Simplifying Patient Communication in Hematology and Oncology","oncOPAL","Inclusion Criteria:\n\n* Age 18 years or older\n* Inpatient of the Department of Medicine III (Hematology\u002FOncology) at TUM University Hospital (Klinikum rechts der Isar), Munich, Germany\n* Receipt of a discharge letter including the sections Current Status, Medical History, Epicrisis, and Further Management as part of routine clinical care\n* Capacity to provide informed consent\n* Written informed consent following the consent procedure\n\nExclusion Criteria:\n\n* Cognitive impairment precluding independent assessment of comprehension (e.g., dementia, severe encephalopathy)\n* Participation in another study with potential influence on the study endpoints\n* Lack of capacity to provide informed consent\n* Refusal to participate in the study",{"count":280,"type":21},150,[103],"This study tests whether patients with blood cancer or other cancers better understand their medical information when it is rewritten in plain language by an artificial intelligence (AI) system.\n\nWhen patients are discharged from the hospital, they receive a medical letter summarizing their diagnosis, treatment, and next steps. These letters are often written in technical language that is difficult for patients to understand. In this study, an AI language model running on the hospital's own secure servers rewrites parts of this letter into simpler language. A physician checks the simplified version before the patient receives it.\n\nPatients are randomly assigned to one of two groups. One group receives both the standard medical letter and the AI-simplified version. The other group receives the standard letter only. A separate group of patients who do not speak German well will receive a simplified and translated version.\n\nAfter reading their letter, all participants fill out a short questionnaire about how well they understood the information. The study takes place at TUM University Hospital (Klinikum rechts der Isar) in Munich, Germany.",[28,284],"Oncologic Disorders",[286,287,288],"Patient-Provider Communication","Patient Health Literacy","Large Language Model","2026-04-13",{"date":262,"type":40},{"date":292,"type":40},"2026-04-01",{"date":294,"type":21},"2027-04-01",{"name":296,"class":118},"Technical University of Munich",{"id":298,"slug":299,"hasResults":11,"nctId":300,"briefTitle":301,"officialTitle":302,"acronym":4,"eligibilityCriteria":303,"healthyVolunteers":11,"sex":16,"minAge":69,"maxAge":4,"enrollmentInfo":304,"targetDuration":4,"studyType":22,"phases":306,"briefSummary":307,"conditions":308,"keywords":309,"overallStatus":83,"whyStopped":4,"lastUpdateSubmitDate":314,"lastUpdatePostDateStruct":315,"startDateStruct":317,"completionDateStruct":319,"leadSponsor":321,"locationsCount":48},"100342237","mind-body-medicine-for-patients-with-malignant-hematological-diseases-100342237","NCT03735992","Mind-body Medicine for Patients With Malignant Hematological Diseases","Mind-body Medicine as a Supportive Strategy for Patients With Malignant Hematological Diseases: a Randomized Controlled Trial","Inclusion Criteria:\n\n* Patients with malignant hematological diseases in complete remission after primary chemotherapy and\u002For radiation\n* Physical and mental ability to attent 8 of 11 group units\n\nExclusion Criteria:\n\n* Chemotherapy, radiation, or rehabilitation programm during the study period\n* Pregnancy\n* Participation in other studies with behavioral interventions during the study period",{"count":305,"type":21},94,[103],"This randomized controlled trial aims to investigate the effectiveness of a mind-body group program as a supprtivemanagement strategy for fatigue in patients with malignant hematological diseases.",[28],[28,310,311,312,313],"Supportive Therapy","Fatigue","Mind-body medicine","Complementary and alternative medicine","2026-04-10",{"date":316,"type":40},"2026-04-15",{"date":318,"type":40},"2017-09-06",{"date":320,"type":21},"2026-12-31",{"name":322,"class":118},"Universität Duisburg-Essen",{"id":324,"slug":325,"hasResults":11,"nctId":326,"briefTitle":327,"officialTitle":328,"acronym":4,"eligibilityCriteria":329,"healthyVolunteers":11,"sex":16,"minAge":69,"maxAge":4,"enrollmentInfo":330,"targetDuration":4,"studyType":131,"phases":4,"briefSummary":332,"conditions":333,"keywords":4,"overallStatus":83,"whyStopped":4,"lastUpdateSubmitDate":335,"lastUpdatePostDateStruct":336,"startDateStruct":337,"completionDateStruct":339,"leadSponsor":341,"locationsCount":48},"100287556","uwccc-molecular-tumor-board-registry-100287556","NCT03023202","UWCCC Molecular Tumor Board Registry","UWCCC Precision Medicine Molecular Tumor Board Registry","Inclusion Criteria:\n\n* Clinically suspected or histologically confirmed solid or hematological malignancy\n* Undergoing genetic testing of tumor\n* Ability to understand written informed consent document\n* Willingness to sign written informed consent document\n\nExclusion Criteria:\n\n* Pediatric patients (age\\\u003C18 years) will be excluded due to a lack of expertise on the molecular tumor committee",{"count":331,"type":21},10000,"This study seeks to evaluate the clinical utility of the Precision Medicine Molecular Tumor Board, and to track patient outcomes.",[28,334],"Solid Neoplasm","2026-04-07",{"date":289,"type":40},{"date":338,"type":40},"2016-03-30",{"date":340,"type":21},"2029-03",{"name":342,"class":118},"University of Wisconsin, Madison",{"id":344,"slug":345,"hasResults":11,"nctId":346,"briefTitle":347,"officialTitle":348,"acronym":349,"eligibilityCriteria":350,"healthyVolunteers":11,"sex":16,"minAge":351,"maxAge":4,"enrollmentInfo":352,"targetDuration":4,"studyType":22,"phases":353,"briefSummary":355,"conditions":356,"keywords":4,"overallStatus":83,"whyStopped":4,"lastUpdateSubmitDate":359,"lastUpdatePostDateStruct":360,"startDateStruct":362,"completionDateStruct":364,"leadSponsor":366,"locationsCount":48},"100630298","phase-3-influenza-vaccination-strategy-for-patients-with-hematologic-malignancy-100630298","NCT07485855","Influenza Vaccination Strategy for Patients With Hematologic Malignancy","Comparison of Immunogenicity of Different Influenza Vaccines in Patients With Hematologic Malignancies","(HEM-FLU)","Inclusion Criteria:\n\n* Adults aged 19 years or older\n* Confirmed diagnosis of hematologic malignancy, including:\n\nnon-Hodgkin lymphoma, Hodgkin lymphoma, acute leukemia, chronic leukemia, or plasma cell disorders\n\nExclusion Criteria:\n\n* Difficulty with repeated venipuncture or blood sampling (e.g., poor vascular access or bleeding tendency)\n* Cognitive or psychiatric impairment precluding understanding of or cooperation with study procedures\n* Known hypersensitivity to influenza vaccine components\n* Influenza vaccination within the preceding 6 months\n* Any other condition deemed clinically inappropriate for study participation at investigator discretion","19 Years",{"count":250,"type":21},[354],"PHASE3","This randomized controlled trial evaluates and compares the immunogenicity of three different influenza vaccine formulations: high-dose trivalent (HD-IIV3), MF59-adjuvanted quadrivalent (aIIV4), and standard-dose trivalent (SD-IIV3) vaccines. The study population consists of patients with hematologic malignancies, including those undergoing autologous stem cell transplantation or CAR-T cell therapy. The primary goal is to identify which vaccine strategy elicits the most robust antibody and T cell-mediated immune responses in this severely immunocompromised population",[28,357,358],"Influenza","Immunogenicity","2026-03-20",{"date":361,"type":40},"2026-03-24",{"date":363,"type":40},"2025-12-04",{"date":365,"type":21},"2028-04-30",{"name":367,"class":118},"Asan Medical Center",{"id":369,"slug":370,"hasResults":11,"nctId":371,"briefTitle":372,"officialTitle":372,"acronym":4,"eligibilityCriteria":373,"healthyVolunteers":11,"sex":16,"minAge":69,"maxAge":4,"enrollmentInfo":374,"targetDuration":4,"studyType":22,"phases":376,"briefSummary":377,"conditions":378,"keywords":4,"overallStatus":83,"whyStopped":4,"lastUpdateSubmitDate":391,"lastUpdatePostDateStruct":392,"startDateStruct":394,"completionDateStruct":396,"leadSponsor":398,"locationsCount":197},"100282586","pre-myeloid-cancer-and-bone-marrow-failure-clinic-study-100282586","NCT02958462","Pre-myeloid Cancer and Bone Marrow Failure Clinic Study","Inclusion Criteria:\n\n* Patients with idiopathic cytopenias of unclear significance (ICUS)\n* Patients with clonal hematopoiesis of indeterminate significance (clonal hematopoiesis of indeterminate potential \\[CHIP\\]), including the recently described CHIP syndrome called VEXAS (vacuoles, E1 ubiquitin ligase, X chromosomal, autoimmune and somatic)\n* Patients with clonal cytopenias of undetermined significance (CCUS)\n* Marrow failure syndromes with myeloid malignancy predisposition - telomere dysfunction, chromosomal breakage disorders\n* Germ line inherited syndromes with risk for malignant transformation - GATA2, CEBPA, ETV-6, RUNX1, JAK2, PF6, etc.\n* Low risk MDS (idiopathic dysplasia of unclear significance)\n* Family member of a patient with one of the above conditions\n* Patient at high risk or suspected of developing one of the above conditions\n\nExclusion Criteria:\n\n* Patients under 18 years of age",{"count":375,"type":21},2000,[103],"This clinical trial tests next generation sequencing (NGS) for the detection of precursor features of pre-myeloid cancers and bone marrow failure syndromes. NGS is a procedure that looks at relevant cancer associated genes and what they do. Finding genetic markers for pre-malignant conditions may help identify patients who are at risk of pre-myeloid cancers and bone marrow failure syndromes and lead to earlier intervention.",[379,380,381,382,383,384,385,28,386,387,388,389,390],"Myeloid Malignancy","Inherited Bone Marrow Failure Syndrome","Clonal Expansion","Cytopenia","Bone Marrow Failure Syndrome","Clonal Cytopenia of Undetermined Significance","Clonal Hematopoiesis of Indeterminate Potential","Hematopoietic and Lymphatic System Neoplasm","Hereditary Neoplastic Syndrome","Idiopathic Cytopenia of Undetermined Significance","Idiopathic Dysplasia of Uncertain Significance","Low Risk Myelodysplastic Syndrome","2026-02-20",{"date":393,"type":40},"2026-02-23",{"date":395,"type":40},"2017-01-16",{"date":397,"type":21},"2035-09-15",{"name":399,"class":118},"Mayo Clinic",{"id":401,"slug":402,"hasResults":11,"nctId":403,"briefTitle":404,"officialTitle":405,"acronym":4,"eligibilityCriteria":406,"healthyVolunteers":11,"sex":16,"minAge":69,"maxAge":4,"enrollmentInfo":407,"targetDuration":4,"studyType":22,"phases":408,"briefSummary":409,"conditions":410,"keywords":411,"overallStatus":83,"whyStopped":4,"lastUpdateSubmitDate":415,"lastUpdatePostDateStruct":416,"startDateStruct":418,"completionDateStruct":420,"leadSponsor":422,"locationsCount":48},"100568793","comparison-of-hemanext-one-system-and-conventional-red-blood-cell-transfusion-100568793","NCT06685848","Comparison of Hemanext ONE® System and Conventional Red Blood Cell Transfusion","Multi-Center, Randomized, Controlled Cross-Over Study to Evaluate Safety and Effectiveness of Hypoxic RBCs Processed With the Hemanext ONE System vs Conventional RBCs in Patients With Transfusion-Dependent Haematological Malignancies","Inclusion Criteria:\n\n* Male or female aged 18 or older\n* Patients with a documented diagnosis of a haematological malignancy requiring chronic transfusions.\n* If MDS patient, Have low risk or intermediate risk MDS per either IPSS-R (https:\u002F\u002Fwww.mds-foundation.org\u002Fipss-r-calculator\u002F) or IPSS-M (IPSS-M Risk Calculator (mds-risk-model.com))\n* If MDS patient, a bone marrow aspirate completed within the 6 months prior to study enrolment, and which did not show progression to higher risk MDS\n* Have RBC transfusion dependence (at least 2 RBC units \u002F8 weeks during the last 16 weeks)\n* Baseline RBC transfusion threshold of 9 g\u002FdL\n* ECOG (Eastern Cooperative Oncology Group) performance status \\< 3\n* Have signed the informed consent form and are willing to comply with the study visits and procedures\n* If on Iron Chelation Therapy, have been on a stable dose for ≥3 months prior to screening\n\nExclusion Criteria:\n\n* Have a life expectancy of less than 1 year\n* Have palpable splenomegaly (more than 3 cm below the mid clavicular line)\n* Have other associated causes of anemia (including auto-immune hemolysis or active hemorrhage, or progression to acute leukemia)\n* If prescribed erythropoiesis affecting disease modifying agents (e.g. G-CSF, erythropoietin), have not been on a stable dose for 90 days\n* Is currently taking Luspatercept or other investigational erythropoiesis affecting disease modifying agent\n* Have severe renal insufficiency with creatinine clearance (MDRD or CKD EPI) below 30ml\u002Fmin\n* Have lung disease with hypoxia or oxygen-dependent\n* Have severe coronary artery disease (including unstable angina or recent myocardial infraction) or severe heart failure (left ventricular ejection fraction less than 30%)\n* Have a history of cancer active in the previous 3 years, except local cervix cancer, or basal cell cutaneous carcinoma\n* Have a history of allo-immunization other than rhesus Kell that cannot be managed by the local blood bank\n* Are a female of child-bearing potential that is pregnant, planning to become pregnant in the next 14 months or breastfeeding\n* Are a patient under guardianship or curatorship\n* Are currently participating in another interventional study evaluating an erythropoiesis affecting disease modifying agent",{"count":5,"type":21},[103],"The overall objective of this study is to collect preliminary effectiveness and safety data on the transfusion of hypoxic RBCs, manufactured with the Hemanext ONE device, in patients with hematological malignancies. The Hemanext ONE device received CE mark in April 2021.",[28],[412,413,414],"Transfusion","Red Blood Cells","Hypoxic","2026-01-06",{"date":417,"type":40},"2026-01-07",{"date":419,"type":40},"2024-11-29",{"date":421,"type":21},"2026-12-15",{"name":423,"class":196},"Hemanext",{"id":425,"slug":426,"hasResults":11,"nctId":427,"briefTitle":428,"officialTitle":429,"acronym":430,"eligibilityCriteria":431,"healthyVolunteers":11,"sex":16,"minAge":69,"maxAge":4,"enrollmentInfo":432,"targetDuration":4,"studyType":22,"phases":434,"briefSummary":435,"conditions":436,"keywords":4,"overallStatus":83,"whyStopped":4,"lastUpdateSubmitDate":415,"lastUpdatePostDateStruct":437,"startDateStruct":439,"completionDateStruct":441,"leadSponsor":443,"locationsCount":445},"100396905","phase-3-platelet-transfusions-in-hematopoietic-stem-cell-transplantation-the-path-iii-trial-100396905","NCT04448184","Platelet Transfusions in Hematopoietic Stem Cell Transplantation (The PATH III Trial)","Platelet Transfusions in Hematopoietic Stem Cell Transplantation - The PATH Phase III Trial","PATH","Inclusion Criteria:\n\n1. Adults 18 years or older undergoing ASCT for a hematologic malignancy\n2. Patients providing written informed consent prior to starting transplantation\n\nExclusion Criteria:\n\n1. A previous WHO grade 2, 3 or 4 bleeding event within the past year\n2. A previous or current unprovoked thrombotic event defined as a pulmonary embolism, deep vein thrombosis, cerebral thrombosis\n3. A current provoked thrombotic event (e.g. catheter-related thrombosis) within last month and\u002For still requiring anticoagulant treatment.\n4. A requirement for therapeutic anticoagulant or anti-platelet drugs during ASCT\n5. Active angina (chest pain of presumed cardiac origin either at rest or with activity)\n6. Current or previous (within 2 weeks) urinary tract bleeding\n7. An inherited hemostatic or thrombotic disorder\n8. Coagulopathy defined as a prothrombin time '\u002FInternational Normalization Ratio (INR) or activated partial thromboplastin time more than 1.5 times the upper limit of normal or fibrinogen less than 2 g\u002FL\n9. Previously documented history of refractoriness to platelet transfusion secondary to HLA antibodies (Refractoriness is defined as 2 consecutive ABO matched platelet transfusions with platelet increment of \\\u003C 7.5 and the presence of anti-HLA antibodies)\n10. Significant renal impairment (creatinine more than 1.5 times the upper limit of normal or a eGFR less than 0.5 mL\u002Fmin\u002F1.78m2)\n11. Pregnant or breast-feeding\n12. Unwilling or unable to provide informed consent\n13. Participant has acquired disturbances to his\u002Fher colour vision (does not apply to congenital colour blindness)\n14. Participant has known sensitivity or allergy to Tranexamic Acid or any of its ingredients",{"count":433,"type":21},662,[354],"It is hypothesized that a strategy using prophylactic oral and intravenous Tranexamic Acid (TXA) with therapeutic platelet transfusions (if required) is safe and more effective than prophylactic platelet transfusions in patients undergoing an autologous hematopoietic stem cell transplantation (ASCT).",[28],{"date":438,"type":40},"2026-01-08",{"date":440,"type":40},"2022-02-16",{"date":442,"type":21},"2027-02",{"name":444,"class":118},"Ottawa Hospital Research Institute",12,{"id":447,"slug":448,"hasResults":11,"nctId":449,"briefTitle":450,"officialTitle":450,"acronym":451,"eligibilityCriteria":452,"healthyVolunteers":11,"sex":16,"minAge":69,"maxAge":4,"enrollmentInfo":453,"targetDuration":4,"studyType":131,"phases":4,"briefSummary":454,"conditions":455,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":458,"lastUpdatePostDateStruct":459,"startDateStruct":461,"completionDateStruct":463,"leadSponsor":465,"locationsCount":48},"100610980","role-of-fibrinolytic-activity-in-neoplastic-pathologies-complicated-by-coagulopathy-100610980","NCT07234630","Role of Fibrinolytic Activity in Neoplastic Pathologies Complicated by Coagulopathy","NEO-COAG","Inclusion Criteria:\n\nFor all groups:\n\n* Age \\> 18 years\n* Patient hospitalized in Emergency Medicine, Intensive Care Medicine or Hematology\u002FOncology Intensive Care, Hematology\u002FOncology Service or Hepatobiliary and Digestive Surgery Service\n* Coagulopathy defined by the combination of thrombocytopenia (\\\u003C 100 G\u002FL) and increased INR (\\>1.2)\n\nGroup 1: Malignant hemopathies with large tumor masses:\n\n* Acute myeloblastic or lymphoblastic leukemia with leukocyte count (or blasts) \\>50G\u002FL in peripheral blood, or\n* Lymphoma documented by tissue biopsy, with biological tumor lysis syndrome, diagnosed according to Cairo and Bishop criteria (3).\n\nGroup 2: Locally advanced or metastatic solid tumors with DIC:\n\n* Prostatic adenocarcinoma\n* Malignant pancreatic or biliary tract tumor (cholangiocarcinoma),\n* Scheduled complex hepatobiliary carcinological surgery,\n* Metastatic adenocarcinoma of the digestive tract.\n\nGroup 3: Control group (free of neoplastic pathology, with well-studied coagulopathy): Septic shock\n\nExclusion Criteria:\n\n* Patient under protective supervision (guardianship or curatorship)\n* Pregnant women\n* Patients weighing less than 50 kg\n* Patient already included in the study\n* Congenital hemostasis disorders\n* Active bleeding at the time of inclusion\n* Patient with cirrhosis\n* Patients receiving curative anticoagulation therapy\n* Patients with a spontaneous INR \\> 1.2 in a previous blood test in a context of fibrinolytic insufficiency\n* Each group is exclusive of the other, for example :\n\nFor Group 1 (Neoplastic pathologies): Presence of documented sepsis at the time of inclusion",{"count":280,"type":21},"The aim of this research is to measure fibrinolytic activity in neoplastic pathologies in order to provide preliminary data on which to base a future, larger-scale study to determine predictive markers of complication in order to improve patient management.\n\nPrimary purpose: measure plasminogen concentration on day 1 in subjects diagnosed with malignant hematological disease, solid tumors, or septic shock, with coagulopathy.\n\nSecondary purpose:\n\n* Estimate the difference in plasminogen concentration at D1 in patients with coagulopathy between subjects with a diagnosis of haematological malignancy and those with solid tumor\n* Estimate the difference in plasminogen concentration at D1 in patients with coagulopathy between subjects with a diagnosis of haematological malignancy and those with septic shock\n* Estimate the difference in plasminogen concentration on Day 1 in patients with coagulopathy between subjects with a diagnosis of solid tumor and those with septic shock.\n\nIn the 3 groups, subjects with a diagnosis of haematological malignancy, solid tumor, septic shock, presenting with coagulopathy:\n\n* Evaluate the correlation between the concentration of circulating plasminogen active on Day 1 and the occurrence of a bleeding complication within 28 days of admission to critical care.\n* Evaluate the correlation between the concentration of circulating plasminogen active on Day 1 and the occurrence of a thrombotic complication, within 28 days of admission to critical care.\n* Evaluate the predictive performance of circulating active plasminogen concentration on Day 1 in the need for extra renal purification within 28 days of admission to critical care.\n* Estimate the differences at each time point (D1, D3, D7) in haemostasis markers and markers of fibrinolytic activity and its regulation.\n\nAssess the link between fibrinolytic activity and :\n\n* The diagnosis of disseminated intravascular coagulation (DIC),\n* The risk of haemorrhage\n* Risk of organ failures\n* Thrombotic risk\n* Risk of organ failure\n* Neutrophile activation and circulating NETs levels",[28,456,457],"Solid Tumor Metastatic Cancer Advanced Cancer","Disseminated Intravascular Coagulation","2025-12-09",{"date":460,"type":40},"2025-12-10",{"date":462,"type":21},"2026-01",{"date":464,"type":21},"2028-02",{"name":466,"class":118},"University Hospital, Strasbourg, France",{"id":468,"slug":469,"hasResults":11,"nctId":470,"briefTitle":471,"officialTitle":472,"acronym":4,"eligibilityCriteria":473,"healthyVolunteers":11,"sex":16,"minAge":69,"maxAge":4,"enrollmentInfo":474,"targetDuration":4,"studyType":131,"phases":4,"briefSummary":476,"conditions":477,"keywords":4,"overallStatus":83,"whyStopped":4,"lastUpdateSubmitDate":482,"lastUpdatePostDateStruct":483,"startDateStruct":485,"completionDateStruct":487,"leadSponsor":489,"locationsCount":48},"100549387","a-multi-center-investigation-of-family-health-100549387","NCT06433349","A Multi-center Investigation of Family Health.","A Multi-center Investigation of Family Health, Needs, Perceived Support, Self-efficacy and Quality of Life During the Cancer Trajectory: A Longitudinal Mixed Methods Study Among Danish Cancer Patients and Their Caregivers","Inclusion Criteria:\n\n* curative intended patients and their eventual appointed caregivers \\>18\n* breast-, prostate- colorectal cancer or lymphoma.\n\nExclusion Criteria:\n\n* Not able to understand or give written informed consent\n* Not able to speak Danish or complete questionnaires in Danish",{"count":475,"type":21},240,"The current healthcare system is unable to identify burdened and vulnerable families affected by cancer, partly due to a lack of knowledge of how cancer affects family health during treatment and survivorship. Recent reviews have documented a general lack of cancer studies including both the patient and the family, and a particular deficiency in studies including more than the spouse.\n\nThe principal aim of this study is to investigate family health, needs and perceived support, quality of life, self-efficacy, depression, stress and resilience in both patients with cancer and their families across the cancer trajectory. Additionally, the study seeks to identify particularly burdened and vulnerable families and investigate contributing factors to their vulnerability.",[478,479,480,28,481],"Breast Cancer","Prostate Cancer","Colorectal Cancer","Caregivers","2025-09-30",{"date":484,"type":40},"2025-10-06",{"date":486,"type":40},"2024-05-13",{"date":488,"type":21},"2028-12-31",{"name":490,"class":118},"Odense University Hospital",{"id":492,"slug":493,"hasResults":11,"nctId":494,"briefTitle":495,"officialTitle":496,"acronym":4,"eligibilityCriteria":497,"healthyVolunteers":11,"sex":16,"minAge":69,"maxAge":4,"enrollmentInfo":498,"targetDuration":4,"studyType":22,"phases":499,"briefSummary":500,"conditions":501,"keywords":505,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":508,"lastUpdatePostDateStruct":509,"startDateStruct":511,"completionDateStruct":513,"leadSponsor":514,"locationsCount":4},"100606710","the-effect-of-a-protective-oral-care-protocol-using-peppermint-oil-mouthwash-100606710","NCT07179094","The Effect of a Protective Oral Care Protocol Using Peppermint Oil Mouthwash","The Effect of a Protective Oral Care Protocol Using Peppermint Oil Mouthwash on Chemotherapy-Induced Nausea, Vomiting, and Loss of Appetite in Patients With Hematologic Malignancies","Inclusion Criteria:\n\n* Age 18 years or older\n* Clinical diagnosis of hematologic malignancy\n* History of at least one chemotherapy cycle\n* Scheduled to receive chemotherapy with high or moderate emetogenic risk agents\n* No oral mucositis before chemotherapy\n* No metastasis\n* Literate (able to read and write)\n* Volunteer to participate in the study\n\nExclusion Criteria:\n\n* Use of herbal remedies for nausea, vomiting, or anorexia\n* Concurrent radiotherapy with chemotherapy\n* Non-adherence to standard antiemetic therapy according to the chemotherapy preparation regimen and protocol (e.g., use of antiemetics other than granisetron or metoclopramide)\n* Known allergy to peppermint oil\n* Psychiatric disorders\n* Communication impairments (hearing or speech difficulties)\n* Altered level of consciousness\n* Endotracheal intubation\n* Requirement for oral care solutions other than the clinic's routine procedures (saline or sodium bicarbonate)\n* Chronic gastrointestinal diseases (gastritis, gastric\u002Fpeptic ulcer, ulcerative colitis, Crohn's disease, gastroesophageal reflux, irritable bowel syndrome, cirrhosis, or pancreatitis)\n* Migraine\n* Brain metastases\n* Hepatic or renal insufficiency\n* Administration of low-emetogenic chemotherapy\n* Mucositis (Oral Assessment Guide score: 15-24 points)",{"count":229,"type":21},[103],"Hematologic malignancies are the fifth most common type of cancer in the world. Patients with hematologic malignancies receive long-term and exhausting treatments such as chemotherapy, radiotherapy, hematopoietic stem cell transplantation and supportive therapies. Chemotherapy-induced nausea and vomiting has a significant impact on the daily lives of patients and causes physiological effects such as anorexia, malnutrition, weight loss, dehydration and electrolyte imbalance. It also has a negative impact on activities of daily living and psychological status, and may lead to poor adherence to chemotherapy regimens, refusal of chemotherapy or discontinuation of treatment. Oral mucosa is one of the areas most affected by the cytotoxic damage of chemotherapy. Disruption of the oral mucosa causes nausea, vomiting and feeding problems. Patients resort to non-drug approaches to manage these problems. It is important that these non-pharmacologic approaches are supported and controlled by reliable and evidence-based studies in order to prevent adverse effects on patient outcomes. In the literature, it has been determined that peppermint oil has antiemetic, antiseptic, anti-inflammatory, analgesic, antiseptic, antioxidant, antiviral, antifungal and spasmolytic effects, protects the integrity of the oral mucosa and has positive effects on nausea-vomiting and anorexia.\n\nIn this context, the aim of the study was to investigate the effect of a preventive oral care protocol with peppermint oil mouthwash on chemotherapy-induced nausea, vomiting and appetite in patients with hematologic malignancy.\n\nResearch Hypotheses H01: The protective oral care protocol applied with peppermint oil in patients with hematological malignancies has no effect on the development of chemotherapy-induced nausea and vomiting.\n\nH02: The protective oral care protocol applied with peppermint oil in patients with hematological malignancies has no effect on the severity of chemotherapy-induced nausea and vomiting.\n\nH03: The protective oral care protocol applied with peppermint oil in patients with hematological malignancies has no effect on the development of chemotherapy-induced anorexia.\n\nH04: The protective oral care protocol applied with peppermint oil in patients with hematological malignancies has no effect on the severity of chemotherapy-induced anorexia.\n\nMethods: The type of study is a single-blind randomized controlled experimental study. The research will be conducted between September 10, 2025, and April 10, 2026, with patients admitted to the hematology clinic of a university hospital for chemotherapy treatment. The study will be conducted with a total of 72 people who will be randomly assigned to the intervention (n=36) and control groups (n=36) by stratified and block randomization method. Patients who are 18 years of age or older, have hematologic malignancy, with a history of at least one chemotherapy cycle, and scheduled to receive chemotherapy with high or moderate emetogenic risk agents, do not have oral mucositis before chemotherapy, do not have metastasis, are literate and volunteer to participate in the study will be included in the study. Research data will be collected using the \"Patient Introduction Form\", \"Rhodes Nausea-Vomiting and Retching Index\", \"Oral Assessment Guide\", \"Appetite Assessment Chart \\[(Visual Analog Scale (VAS)\\]\", \"Peppermint Oil Protective Oral Care Protocol\", \"Food Intake Record Form\", \"Allergic Reaction Monitoring Form\" and \"Patient Monitoring Form and Antiemetic Record Chart\". In addition to the routine protective oral care (saline solution mouthwash and\u002For sodium bicarbonate mouthwash) in the clinic, \"Peppermint Oil Protective Oral Care Protocol\" will be applied to the intervention group for 6 days from the start of chemotherapy treatment. Patients will receive mouthwash prepared with 1 ml of peppermint oil and 50 ml of prepared drinking water 3 times a day. Patients in the intervention group will be monitored for 6 days by evaluating oral assessment, development of oral mucositis, appetite follow-up and compliance with mouthwash. The development of allergy due to the use of peppermint oil in each mouthwash application will be evaluated. The control group will not receive any oral care intervention by the researcher and will receive routine preventive oral care in the clinic. In the evaluation of the data, descriptive statistics, Chi-square \u002F Fisher's Exact test will be used for the relationship between categorical variables, Mann Whitney U test, Wilcoxon test, Kruskal-Wallis H test will be used for the relationship between continuous variables in groups that do not show normal distribution; one-way analysis of variance \u002F repeated measures analysis of variance, t test for dependent and independent groups will be used in groups with normal distribution. Correlation analysis and regression analysis will be used to examine the relationship between variables.",[28,502,503,504],"Nausea","Vomiting","Anorexia",[28,502,503,504,506,507],"Prevention Mouthrinse","peppermint oil","2025-09-15",{"date":510,"type":40},"2025-09-17",{"date":512,"type":21},"2025-09-10",{"date":166,"type":21},{"name":515,"class":118},"Şule Güzle",{"id":517,"slug":518,"hasResults":11,"nctId":519,"briefTitle":520,"officialTitle":521,"acronym":522,"eligibilityCriteria":523,"healthyVolunteers":11,"sex":16,"minAge":69,"maxAge":4,"enrollmentInfo":524,"targetDuration":4,"studyType":22,"phases":526,"briefSummary":527,"conditions":528,"keywords":529,"overallStatus":83,"whyStopped":4,"lastUpdateSubmitDate":535,"lastUpdatePostDateStruct":536,"startDateStruct":538,"completionDateStruct":540,"leadSponsor":542,"locationsCount":48},"100415565","microbiome-in-cancer-patients-with-high-dose-chemotherapy-with-stem-cell-transplantation-100415565","NCT04691284","Microbiome in Cancer Patients With High Dose Chemotherapy With Stem Cell Transplantation","Microbiome in Cancer Patients Undergoing High Dose Chemotherapy With Stem Cell Transplantation","SCTMICROBIOM","Inclusion Criteria:\n\n* signed written informed consent\n* aged 18 years or older\n* patients planned to be treated by high-dose chemotherapy and hematopoietic cell transplantation or by CAR-T cell therapy in National Cancer Institute, Slovakia\n\nExclusion Criteria:\n\n\\- patients not-matching inclusion criteria",{"count":525,"type":21},100,[103],"Numerous in vitro and animal studies as well as growing number of clinical studies support the important role of microbiome in carcinogenesis and cancer treatment. Detection of changes in patients´ microbiome following hematopoietic cell transplantation\u002FCAR-T cell therapy and correlations with adverse transplant outcomes, mainly infectious complications, acute and chronic GvHD, disease recurrence etc. could serve as predictive markers of immune recovery and treatment response.",[28],[530,531,532,533,534],"Cancer","microbiome","high dose chemotherapy","stem cell transplantation","CAR-T cell","2025-05-22",{"date":537,"type":40},"2025-05-29",{"date":539,"type":40},"2021-03-01",{"date":541,"type":21},"2026-12",{"name":543,"class":544},"National Cancer Institute, Slovakia","OTHER_GOV",{"id":546,"slug":547,"hasResults":11,"nctId":548,"briefTitle":549,"officialTitle":550,"acronym":551,"eligibilityCriteria":552,"healthyVolunteers":126,"sex":16,"minAge":69,"maxAge":4,"enrollmentInfo":553,"targetDuration":4,"studyType":131,"phases":4,"briefSummary":555,"conditions":556,"keywords":4,"overallStatus":83,"whyStopped":4,"lastUpdateSubmitDate":560,"lastUpdatePostDateStruct":561,"startDateStruct":563,"completionDateStruct":565,"leadSponsor":567,"locationsCount":174},"100507037","prospective-validation-of-the-ohi-index-100507037","NCT05882175","Prospective Validation of the OHI Index","A Prospective Study to Validate the Prognostic Power of the Optimized HLH Inflammatory (OHI) Index","HLH","Inclusion Criteria:\n\n* Patients with hematologic malignancies\n* At least 18 years old\n\nExclusion Criteria:\n\n* Prior recent treatment (chemotherapy\u002F other cytoreductive therapies in the last month)",{"count":554,"type":21},300,"Hemophagocytic lymphohistiocytosis (HLH) associated with hematologic malignancies (HM-HLH) is a syndrome with an abysmal prognosis (10-30% 5 years overall survival). The investigators have recently established an improved diagnostic and prognostic index for HM-HLH, termed the Optimized HLH Inflammatory (OHI) index. The OHI index is comprised of the combined elevation of soluble CD25 (sCD25) \\> 3,900 U\u002FmL and ferritin \\>1,000 ng\u002FmL . However, the true incidence and outcomes of HLH\u002FOHI+ in an unselected cohort are unknown, and so is the mechanism of HM-HLH.",[551,557,558,559,28],"Hemophagocytic Lymphohistiocytoses","Hemophagocytic Syndrome","Hematologic Malignancy","2025-05-08",{"date":562,"type":40},"2025-05-13",{"date":564,"type":40},"2021-03-03",{"date":566,"type":21},"2030-03-03",{"name":568,"class":118},"Meir Medical Center",{"id":570,"slug":571,"hasResults":11,"nctId":572,"briefTitle":573,"officialTitle":574,"acronym":4,"eligibilityCriteria":575,"healthyVolunteers":11,"sex":16,"minAge":69,"maxAge":4,"enrollmentInfo":576,"targetDuration":4,"studyType":22,"phases":578,"briefSummary":579,"conditions":580,"keywords":582,"overallStatus":83,"whyStopped":4,"lastUpdateSubmitDate":586,"lastUpdatePostDateStruct":587,"startDateStruct":589,"completionDateStruct":591,"leadSponsor":593,"locationsCount":48},"100548556","ceftolozanetazobactam-vs-piperacillintazobactam-for-the-treatment-of-bacteremia-in-hemato-oncological-patients-100548556","NCT06422533","Ceftolozane\u002FTazobactam vs. Piperacillin\u002FTazobactam for the Treatment of Bacteremia in Hemato-oncological Patients","Ceftolozane\u002FTazobactam vs. Piperacillin\u002FTazobactam for the Treatment of Bacteremia Due to Enterobacteriaceae and Pseudomonas Aeruginosa in Hemato-oncological Patients With Severe Neutropenia and Fever: Non-inferiority Study","Inclusion Criteria:\n\n* All patients \\>18 years old\n* Diagnosis of any hematological malignancy\n* Severe neutropenia (polymorphonuclear \\\u003C500 cells\u002Fmm3)\n* Fever (≥38.3 degrees Celsius in one measure, or ≥38 degrees Celsius in at least two measures)\n* Median arterial pressure ≥65 mmHg on admission\n* A life expectancy ≥ 5 days\n* Agree to participate in the study\n\nExclusion Criteria:\n\n* Known hypersensitivity to cephalosporins or anaphylaxis with beta-lactams\n* Clinical signs related to hemodynamic instability\n* Concomitant use of another antibiotic with activity against Gram-negatives (except Trimethoprim\u002FSulfamethoxazole (TMP\u002FSMX) as prophylaxis for P. jirovecii\n* Patients with end-stage chronic renal failure (\\\u003C10 ml\u002Fmin by creatinine clearance-ACCr) or on renal replacement therapy.\n* Patients with grade IV mucositis",{"count":577,"type":21},226,[103],"Patients with hematological malignancies receive highly myelotoxic chemotherapy regimens that cause periods of severe myelosuppression, which places them at high risk of developing bacteremia.\n\nAt a global level, a very significant increase in multidrug-resistant (MDR) Gram-negative microorganisms, particularly Enterobacteriaceae producing extended-spectrum beta-lactamases (ESBL) and MDR P.aeruginosa, have been described during the last decade. Among the strategies to reduce bacterial resistance, ceftolozane\u002Ftazobactam (C\u002FT) as a \"carbapenem-sparing\" antibiotic has been proposed.\n\nC\u002FT has broad-spectrum activity since it has action against ESBL-producing Enterobacteriaceae and MDR P. aeruginosa. Studies carried out in the real world using this antibiotic in patients with hematological malignancies have demonstrated clinical success in reports and case series, considered a therapeutic option in patients with Enterobacteriaceae and P. aeruginosa infections, particularly in MDR pathogens.\n\nAt the National Cancer Institute (in Spanish, Instituto Nacional de Cancerologia), Gram-negative bacilli have been identified for more than 20 years as the pathogens most frequently associated with bacteremia. Escherichia coli occupies the first place in 25% (41% ESBL), followed by Klebsiella spp. in 5.6% (11.2% ESBL) and P. aeruginosa in 5.6% (11.2% MDR). The protocol for approaching and treating hematological malignancy patients with severe neutropenia and fever is to initiate an antimicrobial regimen with piperacillin\u002Ftazobactam (P\u002FT). In patients who persist with fever after 48 to 72 hours of starting antibiotics, who present with clinical deterioration, or in whom P\u002FT-resistant bacteria are identified, this is escalated to carbapenem.\n\nTherefore, it is proposed to compare the clinical and microbiological response in patients with hematological malignancies who present with severe neutropenia and fever and who present clinical data of bacteremia, with empirical treatment with C\u002FT vs. P\u002FT, trying to reduce the use of carbapenems in this group of patients.",[28,581],"Neutropenia",[583,584,585,107],"ceftolozane\u002Ftazobactam","piperacillin\u002Ftazobactam","neutropenia","2024-06-02",{"date":588,"type":40},"2024-06-04",{"date":590,"type":40},"2023-11-07",{"date":592,"type":21},"2025-08-30",{"name":594,"class":118},"Instituto Nacional de Cancerologia de Mexico",{"id":596,"slug":597,"hasResults":11,"nctId":598,"briefTitle":599,"officialTitle":599,"acronym":600,"eligibilityCriteria":601,"healthyVolunteers":11,"sex":16,"minAge":69,"maxAge":4,"enrollmentInfo":602,"targetDuration":4,"studyType":22,"phases":604,"briefSummary":605,"conditions":606,"keywords":607,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":610,"lastUpdatePostDateStruct":611,"startDateStruct":613,"completionDateStruct":615,"leadSponsor":617,"locationsCount":48},"100443425","immunological-profile-for-patients-treated-with-car-t-cells-100443425","NCT05054231","Immunological Profile for Patients Treated With CAR-T Cells","SI-CART","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Planned injection of CAR-T cells within the scope of marketing authorization\n* Signed informed consent\n* French social security affiliation\n\nExclusion Criteria:\n\n* Pregnant women, or women of childbearing potential (without medically acceptable contraception) or breastfeeding women.\n* Patient in emergency situation, adult under legal protection (patient placed under tutorship, curatorship, or judicial protection) or unable to give his consent\n* Impossibility to comply with trial medical follow-up for geographic, social or psychological reasons",{"count":603,"type":21},500,[103],"In the frame of Si-CART study, blood will be collected from patients treated with CAR-T cells: before (at Day (D)-6 and D0 before cells injection), post infusion at D3, D5,D7, D9, D11, D14, D18, D 21, Month (M) 2 and M12 post injection.\n\nA cerebrospinal fluid sample will also be collected if a Cerebrospinal Fluid Analysis Lumbar puncture is performed",[28],[608,609],"CAR-T cells","Immunological Profile","2021-10-07",{"date":612,"type":40},"2021-10-15",{"date":614,"type":21},"2021-10-05",{"date":616,"type":21},"2026-10-05",{"name":618,"class":118},"Institut Paoli-Calmettes"]